Literature DB >> 1972927

Astemizole and cetirizine in the treatment of seasonal allergic rhinitis: a comparative double-blind, multicentre study.

E Rijntjes1, L Ghys, J P Rihoux.   

Abstract

In a double-blind, multicentre trial, 105 patients with seasonal allergic rhinitis were treated with 10 mg astemizole or 10 mg cetirizine once daily for 4 days. Patients were thereafter allowed to change their treatment if not satisfied with the clinical efficacy. In the cetirizine-treated group, there were significantly fewer (P = 0.02) patients who asked to change their treatment compared to patients receiving astemizole for 4 days. At day 4, there was a significant improvement in the clinical scores for the patients who did not want to change treatment but scores were hardly altered in those patients that wished to change. After treatment for a further 10 days, there was a decrease in all the scored symptoms but this was less marked in the two groups of patients who wanted to change treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972927     DOI: 10.1177/030006059001800306

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  4 in total

Review 1.  Astemizole. A nonsedating antihistamine with fast and sustained activity.

Authors:  M M Janssens
Journal:  Clin Rev Allergy       Date:  1993

Review 2.  Cetirizine. An updated review of its pharmacological properties and therapeutic efficacy.

Authors:  J P Rihoux; S Mariz
Journal:  Clin Rev Allergy       Date:  1993

Review 3.  Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria.

Authors:  D M Campoli-Richards; M M Buckley; A Fitton
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

4.  Inhibition of histamine-induced nasal obstruction by cetirizine in allergic rhinitis.

Authors:  G Braunstein; F Malaquin; I Fajac; M Melac; N Frossard
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.